Draft:Gary Fischer (LSD researcher)
| Submission declined on 16 February 2024 by AngusWOOF (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs to
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Gary M. Fischer (2 June 1931 – 2 March 2012) was a Canadian clinical psychologist known for his pioneering work in the therapeutic use of psychedelic substances, particularly LSD and psilocybin, in the treatment of various mental health conditions.[1]
Early Life and Education[edit]
Gary Fisher was born on June 2, 1931, in Canada. He obtained his Ph.D. in Psychology from the University of Utah, where he laid the foundation for his groundbreaking research in the field of psychotherapy.
Career[edit]
Fisher's interest in the therapeutic potential of psychedelic drugs emerged during his training with the Saskatchewan Group under the guidance of Al Hubbard. In the late 1950s and early 1960s, Fisher conducted revolutionary research, utilizing LSD and psychotherapy to treat children afflicted with autism and schizophrenia.[2] Although controversial, some of Fisher's patients exhibited significant improvement following treatment.[3]
Apart from his work with children, Fisher also explored the use of LSD in assisting terminally ill patients, aiming to alleviate their psychological distress. His efforts in this area earned him recognition for his compassionate approach to end-of-life care. He also collaborated with Timothy Leary in Mexico, the Caribbean, and Millbrook, NY.[4] However, Fisher's research came to an abrupt halt in 1962 when LSD was made illegal, forcing him to discontinue his studies in this field. Nevertheless, his contributions to the understanding of psychedelic-assisted therapy left a lasting impact on the field of psychology.
Fisher served as an assistant professor in the Division of Behavioral Sciences and Healthy Education at the School of Public Health, UCLA. Throughout his career, he authored several influential papers, shedding light on the therapeutic applications of psychedelic compounds in various clinical settings.
Artistic Influence[edit]
In addition to his contributions to psychology, Fisher was also an accomplished artist. He attributed some of his creative inspiration to his own psychedelic experiences, highlighting the profound influence these experiences had on his artistic expression.[1]
References[edit]
- ^ a b "Fisher, Gary, 1931-2012 | Archives and Special Collections". archives.lib.purdue.edu. Retrieved 2024-02-16.
- ^ Standen, Amy; Campbell, Judy (2017-04-11). "The Elementary Kool-Aid Acid Test | KQED". www.kqed.org. Retrieved 2024-02-16.
- ^ "Gary Fisher, psychedelic research pioneer – Psychedelic Salon Podcasts". psychedelicsalon.com. Retrieved 2024-02-16.
- ^ Walsh, Roger; Grob, Charles (2005). Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics. State University of New York Press. ISBN 9780791482964.
Bibliography[edit]
- An Investigation to Determine Therapeutic Effectiveness of LSD-25 and Psilocybin on Hospitalized Severely Emotionally Disturbed Children (10 February 1963), with Daniel Castile, M.D.
- Death, Identity, and Creativity
- "Loneliness" (1969). Psychedelic Review, Number 10, p. 19–20.
- Psychotherapy for the Dying: Principles and Illustrative Cases with Special Reference to the use of LSD (1 April 1970). OMEGA - Journal of Death and Dying, Volume 1, Issue 1, p. 3–15.
- Some Comments Concerning Dosage Levels of Psychedelic Compounds for Psychotherapeutic Experiences (1963). Psychedelic Review, Volume I, Number 2, p. 208–218.
- Successful Outcome of a Single LSD Treatment in a Chronically Dysfunctional Man
- The psycholytic treatment of a childhood schizophrenic girl (1970). International Journal of Social Psychiatry, Volume 16, Issue 2, p.112–130.
- Treatment of Childhood Schizophrenia Utilizing LSD and Psilocybin (1997). Newsletter of the Multidisciplinary Association for Psychedelic Studies (MAPS), Volume 7, Number 3, p. 18–25.